The PancraGEN test is a molecular-based cancer diagnostic test that combines molecular genetic testing with current nongenetic diagnostic methods. It is offered, in conjunction with first-line testing or as a second-line test when first-line testing is equivocal, with the goal of improving diagnosis and management of pancreatic cysts. The PancraGEN test is an offering of Interpace Diagnostics Corporation, subsidiary of PDI Inc. In 2014, PDI Inc. acquired RedPath Integrated Pathology, including their test PathFinderTG for pancreatic cysts. This report will focus on the evidence for PancraGEN and the precursor test,PathFinderTG, to aid in diagnosis and risk determination of the malignant potential of pancreatic cysts.
If you have a Hayes login, click here to view the full report on the Knowledge Center.